- home
- Advanced Search
Filters
Clear All- COVID-19
- 2017-2021
- Publications
- Conference object
- GR
- Frontiers in Public Health
- Europe PubMed Central
- COVID-19
- 2017-2021
- Publications
- Conference object
- GR
- Frontiers in Public Health
- Europe PubMed Central
Loading
description Publicationkeyboard_double_arrow_right Article , Other literature type , Conference object , Preprint 2020Publisher:IEEE Funded by:NIH | Hybrid virtual-MRI/CBCT: ...NIH| Hybrid virtual-MRI/CBCT: A new paradigm for image guidance in liver SBRTAuthors: Floros, Dimitris; Liu, Tiancheng; Pitsianis, Nikos; Sun, Xiaobai;Floros, Dimitris; Liu, Tiancheng; Pitsianis, Nikos; Sun, Xiaobai;We introduce a new method for temporal pattern analysis of scientific collaboration networks. We investigate in particular virus research activities through five epidemic or pandemic outbreaks in the recent two decades and in the ongoing pandemic with COVID-19. Our method embodies two innovative components. The first is a simple model of temporal collaboration networks with time segmented in publication time and convolved in citation history, to effectively capture and accommodate collaboration activities at mixed time scales. The second component is the novel use of graphlets to encode topological structures and to detect change and persistence in collaboration activities over time. We discover in particular two unique and universal roles of bi-fork graphlet in (1) identifying bridges among triangle clusters and (2) quantifying grassroots as the backbone of every collaboration network. We present a number of intriguing patterns and findings about the virus-research activities. Comment: To appear in the Proceedings of High Performance Extreme Computing (HPEC) 2020
WHO Global literatur... arrow_drop_down WHO Global literature on coronavirus diseaseArticle . Conference object . 2020 . Peer-reviewedLicense: IEEE CopyrightarXiv.org e-Print ArchiveOther literature type . Preprint . 2020Data sources: arXiv.org e-Print Archivehttps://doi.org/10.48550/arxiv...Article . 2020License: arXiv Non-Exclusive DistributionData sources: Dataciteadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1109/hpec43674.2020.9286161&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess RoutesGreen bronze 1 citations 1 popularity Average influence Average impulse Average Powered by BIP!more_vert WHO Global literatur... arrow_drop_down WHO Global literature on coronavirus diseaseArticle . Conference object . 2020 . Peer-reviewedLicense: IEEE CopyrightarXiv.org e-Print ArchiveOther literature type . Preprint . 2020Data sources: arXiv.org e-Print Archivehttps://doi.org/10.48550/arxiv...Article . 2020License: arXiv Non-Exclusive DistributionData sources: Dataciteadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1109/hpec43674.2020.9286161&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article , Conference object 2020 FrancePublisher:Georg Thieme Verlag KG Authors: Gerotziafas, Grigoris T.; Sergentanis, Theodoros N.; Voiriot, Guillaume; Lassel, Ludovic; +13 AuthorsGerotziafas, Grigoris T.; Sergentanis, Theodoros N.; Voiriot, Guillaume; Lassel, Ludovic; Papageorgiou, Chryssa; Elabbadi, Alexandre; Turpin, Matthieu; Vandreden, Patrick; Papageorgiou, Loula; Psaltopoulou, Theodora; Terpos, Evangelos; Dimopoulos, Meletios-Athanasios; Parrot, Antoine; Cadranel, Jacques; Pialoux, Gilles; Fartoukh, Muriel; Elalamy, Ismail;AbstractThe prospective observational cohort study COMPASS-COVID-19 aimed to develop a risk assessment model for early identification of hospitalized COVID-19 patients at risk for worsening disease. Patients with confirmed COVID-19 (n = 430) hospitalized between March 18 and April 21, 2020 were divided in derivation (n = 310) and validation (n = 120) cohorts. Two groups became evident: (1) good prognosis group (G-group) with patients hospitalized at the conventional COVID-19 ward and (2) Worsening disease group (W-group) with patients admitted to the intensive care unit (ICU) from the emergency departments. The study end point was disease worsening (acute respiratory failure, shock, myocardial dysfunction, bacterial or viral coinfections, and acute kidney injury) requiring ICU admission. All patients were routinely evaluated for full blood count, prothrombin time, fibrinogen, D-dimers, antithrombin (AT), and protein C activity. Data from the first hospitalization day at the conventional ward or the ICU were analyzed. Cardiovascular risk factors and comorbidities were routinely registered. Obesity, hypertension, diabetes and male gender, increased fibrinogen and D-dimers, thrombocytopenia, AT deficiency, lymphopenia, and an International Society on Thrombosis and Haemostasis (ISTH) score for compensated disseminated intravascular coagulation score (cDIC-ISTH) ≥5 were significant risk factors for worsening disease. The COMPASS-COVID-19 score was derived from multivariate analyses and includes obesity, gender, hemoglobin, lymphocyte, and the cDIC-ISTH score (including platelet count, prothrombin time, D-dimers, AT, and protein C levels). The score has a very good discriminating capacity to stratify patients at high and low risk for worsening disease, with an area under the receiver operating characteristic curve value of 0.77, a sensitivity of 81%, and a specificity of 60%. Application of the COMPASS-COVID-19 score at the validation cohort showed 96% sensitivity. The COMPASS-COVID-19 score is an accurate clinical decision-making tool for an easy identification of COVID-19 patients being at high risk for disease worsening.
Europe PubMed Centra... arrow_drop_down Europe PubMed CentralArticle . 2020Full-Text: http://europepmc.org/articles/PMC7869041Data sources: PubMed CentralThrombosis and HaemostasisArticle . 2020 . Peer-reviewedadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1055/s-0040-1716544&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess RoutesGreen bronze 37 citations 37 popularity Top 1% influence Top 10% impulse Top 1% Powered by BIP!more_vert Europe PubMed Centra... arrow_drop_down Europe PubMed CentralArticle . 2020Full-Text: http://europepmc.org/articles/PMC7869041Data sources: PubMed CentralThrombosis and HaemostasisArticle . 2020 . Peer-reviewedadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1055/s-0040-1716544&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2019 FranceLucie Peyclit; Lucie Peyclit; Sophie Alexandra Baron; Sophie Alexandra Baron; Jean-Marc Rolain; Jean-Marc Rolain;The emergence of new resistance mechanisms, the failure of classical antibiotics in clinic, the decrease in the development of antibiotics in the industry are all challenges that lead us to consider new strategies for the treatment of infectious diseases. Indeed, in recent years controversy has intensified over strains resistant to carbapenem and/or colistin. Various therapeutic solutions are used to overcome administration of last line antibiotics. In this context, drug repurposing, which consists of using a non-antibiotic compound to treat multi-drug resistant bacteria (MDR), is encouraged. In this review, we first report what may have led to drug repurposing. Main definitions, advantages and drawbacks are summarized. Three major methods are described: phenotypic, computational and serendipity. In a second time we will focus on the current knowledge in drug repurposing for carbapenem and colistin-resistant bacteria with different studies describing repurposed compounds tested on Gram-negative bacteria. Furthermore, we show that drug combination therapies can increase successful by drug repurposing strategy. In conclusion, we discuss the pharmaceutical industries that have little interest in reprofiling drugs due to lack of profits. We also consider what a clinician might think of the indications of these uncommon biologists to treat MDR bacterial infections and avoid therapeutic impasses. International audience
Europe PubMed Centra... arrow_drop_down Europe PubMed CentralArticle . 2019Full-Text: http://europepmc.org/articles/PMC6579884Data sources: PubMed CentralFrontiers in Cellular and Infection Microbiology; OpenAPC Global InitiativeArticle . Conference object . 2019 . Peer-reviewedLicense: CC BYHAL Descartes; HAL AMU; Mémoires en Sciences de l'Information et de la Communication; HAL-IRDArticle . 2019License: CC BYadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.3389/fcimb.2019.00193&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess RoutesGreen gold 61 citations 61 popularity Top 1% influence Top 10% impulse Top 1% Powered by BIP!more_vert Europe PubMed Centra... arrow_drop_down Europe PubMed CentralArticle . 2019Full-Text: http://europepmc.org/articles/PMC6579884Data sources: PubMed CentralFrontiers in Cellular and Infection Microbiology; OpenAPC Global InitiativeArticle . Conference object . 2019 . Peer-reviewedLicense: CC BYHAL Descartes; HAL AMU; Mémoires en Sciences de l'Information et de la Communication; HAL-IRDArticle . 2019License: CC BYadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.3389/fcimb.2019.00193&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2018 France Funded by:ANR | MAMMAMIAANR| MAMMAMIAAuthors: Emmanuel Salomon; Marjorie Schmitt; Anil Kumar Marapaka; Athanasios Stamogiannos; +8 AuthorsEmmanuel Salomon; Marjorie Schmitt; Anil Kumar Marapaka; Athanasios Stamogiannos; Germain Revelant; Céline Schmitt; Sarah Alavi; Isabelle Florent; Anthony Addlagatta; Efstratios Stratikos; Céline Tarnus; Sébastien Albrecht;The synthesis of racemic substituted 7-amino-5,7,8,9-tetrahydrobenzocyclohepten-6-one hydrochlorides was optimized to enhance reproducibility and increase the overall yield. In order to investigate their specificity, series of enzyme inhibition assays were carried out against a diversity of proteases, covering representative members of aspartic, cysteine, metallo and serine endopeptidases and including eight members of the monometallic M1 family of aminopeptidases as well as two members of the bimetallic M17 and M28 aminopeptidase families. This aminobenzosuberone scaffold indeed demonstrated selective inhibition of M1 aminopeptidases to the exclusion of other tested protease families it was particularly potent against mammalian APN and its bacterial/parasitic orthologues EcPepN and PfAM1.
Europe PubMed Centra... arrow_drop_down Europe PubMed CentralArticle . 2018Full-Text: http://europepmc.org/articles/PMC6222927Data sources: PubMed CentralMolecules; OpenAPC Global InitiativeOther literature type . Article . Conference object . 2018 . Peer-reviewedLicense: CC BYFull-Text: http://www.mdpi.com/1420-3049/23/10/2607/pdfadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.3390/molecules23102607&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess RoutesGreen gold 9 citations 9 popularity Top 10% influence Average impulse Top 10% Powered by BIP!more_vert Europe PubMed Centra... arrow_drop_down Europe PubMed CentralArticle . 2018Full-Text: http://europepmc.org/articles/PMC6222927Data sources: PubMed CentralMolecules; OpenAPC Global InitiativeOther literature type . Article . Conference object . 2018 . Peer-reviewedLicense: CC BYFull-Text: http://www.mdpi.com/1420-3049/23/10/2607/pdfadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.3390/molecules23102607&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eu
Loading
description Publicationkeyboard_double_arrow_right Article , Other literature type , Conference object , Preprint 2020Publisher:IEEE Funded by:NIH | Hybrid virtual-MRI/CBCT: ...NIH| Hybrid virtual-MRI/CBCT: A new paradigm for image guidance in liver SBRTAuthors: Floros, Dimitris; Liu, Tiancheng; Pitsianis, Nikos; Sun, Xiaobai;Floros, Dimitris; Liu, Tiancheng; Pitsianis, Nikos; Sun, Xiaobai;We introduce a new method for temporal pattern analysis of scientific collaboration networks. We investigate in particular virus research activities through five epidemic or pandemic outbreaks in the recent two decades and in the ongoing pandemic with COVID-19. Our method embodies two innovative components. The first is a simple model of temporal collaboration networks with time segmented in publication time and convolved in citation history, to effectively capture and accommodate collaboration activities at mixed time scales. The second component is the novel use of graphlets to encode topological structures and to detect change and persistence in collaboration activities over time. We discover in particular two unique and universal roles of bi-fork graphlet in (1) identifying bridges among triangle clusters and (2) quantifying grassroots as the backbone of every collaboration network. We present a number of intriguing patterns and findings about the virus-research activities. Comment: To appear in the Proceedings of High Performance Extreme Computing (HPEC) 2020
WHO Global literatur... arrow_drop_down WHO Global literature on coronavirus diseaseArticle . Conference object . 2020 . Peer-reviewedLicense: IEEE CopyrightarXiv.org e-Print ArchiveOther literature type . Preprint . 2020Data sources: arXiv.org e-Print Archivehttps://doi.org/10.48550/arxiv...Article . 2020License: arXiv Non-Exclusive DistributionData sources: Dataciteadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1109/hpec43674.2020.9286161&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess RoutesGreen bronze 1 citations 1 popularity Average influence Average impulse Average Powered by BIP!more_vert WHO Global literatur... arrow_drop_down WHO Global literature on coronavirus diseaseArticle . Conference object . 2020 . Peer-reviewedLicense: IEEE CopyrightarXiv.org e-Print ArchiveOther literature type . Preprint . 2020Data sources: arXiv.org e-Print Archivehttps://doi.org/10.48550/arxiv...Article . 2020License: arXiv Non-Exclusive DistributionData sources: Dataciteadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1109/hpec43674.2020.9286161&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article , Conference object 2020 FrancePublisher:Georg Thieme Verlag KG Authors: Gerotziafas, Grigoris T.; Sergentanis, Theodoros N.; Voiriot, Guillaume; Lassel, Ludovic; +13 AuthorsGerotziafas, Grigoris T.; Sergentanis, Theodoros N.; Voiriot, Guillaume; Lassel, Ludovic; Papageorgiou, Chryssa; Elabbadi, Alexandre; Turpin, Matthieu; Vandreden, Patrick; Papageorgiou, Loula; Psaltopoulou, Theodora; Terpos, Evangelos; Dimopoulos, Meletios-Athanasios; Parrot, Antoine; Cadranel, Jacques; Pialoux, Gilles; Fartoukh, Muriel; Elalamy, Ismail;AbstractThe prospective observational cohort study COMPASS-COVID-19 aimed to develop a risk assessment model for early identification of hospitalized COVID-19 patients at risk for worsening disease. Patients with confirmed COVID-19 (n = 430) hospitalized between March 18 and April 21, 2020 were divided in derivation (n = 310) and validation (n = 120) cohorts. Two groups became evident: (1) good prognosis group (G-group) with patients hospitalized at the conventional COVID-19 ward and (2) Worsening disease group (W-group) with patients admitted to the intensive care unit (ICU) from the emergency departments. The study end point was disease worsening (acute respiratory failure, shock, myocardial dysfunction, bacterial or viral coinfections, and acute kidney injury) requiring ICU admission. All patients were routinely evaluated for full blood count, prothrombin time, fibrinogen, D-dimers, antithrombin (AT), and protein C activity. Data from the first hospitalization day at the conventional ward or the ICU were analyzed. Cardiovascular risk factors and comorbidities were routinely registered. Obesity, hypertension, diabetes and male gender, increased fibrinogen and D-dimers, thrombocytopenia, AT deficiency, lymphopenia, and an International Society on Thrombosis and Haemostasis (ISTH) score for compensated disseminated intravascular coagulation score (cDIC-ISTH) ≥5 were significant risk factors for worsening disease. The COMPASS-COVID-19 score was derived from multivariate analyses and includes obesity, gender, hemoglobin, lymphocyte, and the cDIC-ISTH score (including platelet count, prothrombin time, D-dimers, AT, and protein C levels). The score has a very good discriminating capacity to stratify patients at high and low risk for worsening disease, with an area under the receiver operating characteristic curve value of 0.77, a sensitivity of 81%, and a specificity of 60%. Application of the COMPASS-COVID-19 score at the validation cohort showed 96% sensitivity. The COMPASS-COVID-19 score is an accurate clinical decision-making tool for an easy identification of COVID-19 patients being at high risk for disease worsening.
Europe PubMed Centra... arrow_drop_down Europe PubMed CentralArticle . 2020Full-Text: http://europepmc.org/articles/PMC7869041Data sources: PubMed CentralThrombosis and HaemostasisArticle . 2020 . Peer-reviewedadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1055/s-0040-1716544&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess RoutesGreen bronze 37 citations 37 popularity Top 1% influence Top 10% impulse Top 1% Powered by BIP!more_vert Europe PubMed Centra... arrow_drop_down Europe PubMed CentralArticle . 2020Full-Text: http://europepmc.org/articles/PMC7869041Data sources: PubMed CentralThrombosis and HaemostasisArticle . 2020 . Peer-reviewedadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.1055/s-0040-1716544&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2019 FranceLucie Peyclit; Lucie Peyclit; Sophie Alexandra Baron; Sophie Alexandra Baron; Jean-Marc Rolain; Jean-Marc Rolain;The emergence of new resistance mechanisms, the failure of classical antibiotics in clinic, the decrease in the development of antibiotics in the industry are all challenges that lead us to consider new strategies for the treatment of infectious diseases. Indeed, in recent years controversy has intensified over strains resistant to carbapenem and/or colistin. Various therapeutic solutions are used to overcome administration of last line antibiotics. In this context, drug repurposing, which consists of using a non-antibiotic compound to treat multi-drug resistant bacteria (MDR), is encouraged. In this review, we first report what may have led to drug repurposing. Main definitions, advantages and drawbacks are summarized. Three major methods are described: phenotypic, computational and serendipity. In a second time we will focus on the current knowledge in drug repurposing for carbapenem and colistin-resistant bacteria with different studies describing repurposed compounds tested on Gram-negative bacteria. Furthermore, we show that drug combination therapies can increase successful by drug repurposing strategy. In conclusion, we discuss the pharmaceutical industries that have little interest in reprofiling drugs due to lack of profits. We also consider what a clinician might think of the indications of these uncommon biologists to treat MDR bacterial infections and avoid therapeutic impasses. International audience
Europe PubMed Centra... arrow_drop_down Europe PubMed CentralArticle . 2019Full-Text: http://europepmc.org/articles/PMC6579884Data sources: PubMed CentralFrontiers in Cellular and Infection Microbiology; OpenAPC Global InitiativeArticle . Conference object . 2019 . Peer-reviewedLicense: CC BYHAL Descartes; HAL AMU; Mémoires en Sciences de l'Information et de la Communication; HAL-IRDArticle . 2019License: CC BYadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.3389/fcimb.2019.00193&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess RoutesGreen gold 61 citations 61 popularity Top 1% influence Top 10% impulse Top 1% Powered by BIP!more_vert Europe PubMed Centra... arrow_drop_down Europe PubMed CentralArticle . 2019Full-Text: http://europepmc.org/articles/PMC6579884Data sources: PubMed CentralFrontiers in Cellular and Infection Microbiology; OpenAPC Global InitiativeArticle . Conference object . 2019 . Peer-reviewedLicense: CC BYHAL Descartes; HAL AMU; Mémoires en Sciences de l'Information et de la Communication; HAL-IRDArticle . 2019License: CC BYadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.3389/fcimb.2019.00193&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eudescription Publicationkeyboard_double_arrow_right Article 2018 France Funded by:ANR | MAMMAMIAANR| MAMMAMIAAuthors: Emmanuel Salomon; Marjorie Schmitt; Anil Kumar Marapaka; Athanasios Stamogiannos; +8 AuthorsEmmanuel Salomon; Marjorie Schmitt; Anil Kumar Marapaka; Athanasios Stamogiannos; Germain Revelant; Céline Schmitt; Sarah Alavi; Isabelle Florent; Anthony Addlagatta; Efstratios Stratikos; Céline Tarnus; Sébastien Albrecht;The synthesis of racemic substituted 7-amino-5,7,8,9-tetrahydrobenzocyclohepten-6-one hydrochlorides was optimized to enhance reproducibility and increase the overall yield. In order to investigate their specificity, series of enzyme inhibition assays were carried out against a diversity of proteases, covering representative members of aspartic, cysteine, metallo and serine endopeptidases and including eight members of the monometallic M1 family of aminopeptidases as well as two members of the bimetallic M17 and M28 aminopeptidase families. This aminobenzosuberone scaffold indeed demonstrated selective inhibition of M1 aminopeptidases to the exclusion of other tested protease families it was particularly potent against mammalian APN and its bacterial/parasitic orthologues EcPepN and PfAM1.
Europe PubMed Centra... arrow_drop_down Europe PubMed CentralArticle . 2018Full-Text: http://europepmc.org/articles/PMC6222927Data sources: PubMed CentralMolecules; OpenAPC Global InitiativeOther literature type . Article . Conference object . 2018 . Peer-reviewedLicense: CC BYFull-Text: http://www.mdpi.com/1420-3049/23/10/2607/pdfadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.3390/molecules23102607&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euAccess RoutesGreen gold 9 citations 9 popularity Top 10% influence Average impulse Top 10% Powered by BIP!more_vert Europe PubMed Centra... arrow_drop_down Europe PubMed CentralArticle . 2018Full-Text: http://europepmc.org/articles/PMC6222927Data sources: PubMed CentralMolecules; OpenAPC Global InitiativeOther literature type . Article . Conference object . 2018 . Peer-reviewedLicense: CC BYFull-Text: http://www.mdpi.com/1420-3049/23/10/2607/pdfadd ClaimPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=10.3390/molecules23102607&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eu